Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04040933
Other study ID # CCSTOH001689
Secondary ID CCSTOH001689
Status Completed
Phase N/A
First received
Last updated
Start date August 9, 2019
Est. completion date October 30, 2019

Study information

Verified date June 2023
Source Johnson & Johnson Consumer and Personal Products Worldwide
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the wound healing efficacy (time to complete healing) of different adhesive bandages.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date October 30, 2019
Est. primary completion date October 18, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - Fitzpatrick Skin Type II or III - Uniform skin color on both volar forearms - Generally in good health based on medical history reported by the participant - -Individual has signed the Photographic Release and Informed Consent Documents along with (HIPAA) disclosure - Willing to have temporary (semi-permanent) dot-tattoos applied to the volar forearms Exclusion Criteria: - Has known allergies, hypersensitivity, or adverse reactions to anesthetics, adhesive bandages, latex, wound treatment products, or any component/ingredient present in the Investigational Products (IPs)/auxiliary/ancillary products - Has a known history of a blood-clotting disorder, keloid formation, or a cardiovascular, hepatic, or renal disease - Presents with a skin condition that would, in the opinion of the PI or Study Physician, confound study results, increase risk to participant, or interfere with study evaluations - Has excessive hair or tattoos on either volar forearm - Has a known history of severe systemic immune system disorders - Has self-reported Type 1 or Type 2 diabetes - Has self-reported uncontrolled chronic diseases - Is taking medication that would mask an adverse event, confound study results or alter/compromise the bleeding/healing process - Is self-reported to be pregnant or planning to become pregnant - Has a body mass index (BMI) above 35 - Is self-reported to be an alcohol or drug abuser - Has participated in another clinical trial within 10 days - Either is or lives with someone who is a current employee of any company that makes/markets adhesive bandages or first-aid products

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Marketed Adhesive Bandage #1
On the randomized wound site, a marketed adhesive bandage will be applied.
Marketed Bandage #2
On the randomized wound site, a marketed adhesive bandage will be applied.
Non-Marketed Bandage #1
On the randomized wound site, a non-marketed adhesive bandage will be applied.
Non-Marketed Bandage #2
On the randomized wound site, a non-marketed adhesive bandage will be applied.
Non-Marketed Adhesive Bandage #3
On the randomized wound site, a non-marketed adhesive bandage will be applied.
Non-Marketed Adhesive Bandage #4
On the randomized wound site, a non-marketed adhesive bandage will be applied.
Non-Marketed Adhesive Bandage #5
On the randomized wound site, a non-marketed adhesive bandage will be applied.

Locations

Country Name City State
United States Thomas J. Stephens Richardson Texas

Sponsors (1)

Lead Sponsor Collaborator
Johnson & Johnson Consumer Inc. (J&JCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to Complete Wound Healing Time to complete wound healing: time(in days) elapsed from time of wound creation to 12 PM of day (up to Day 16) on which composite healing score(CHS) first meets complete healing criterion of being at least a score of 8 (threshold for complete healing). CHS was calculated from clinical grading of wound healing parameters as general wound appearance (0 [Poor-New or fresh wound with epithelium layer missing, wound bed appears raw and possibly oozing] to 4 [Excellent-Fully healed, skin flush against surrounding skin, slight color mismatch may be present])+smoothness (0 [Rough, uneven wound]- 4 [complete smoothness, even wound])+epithelial confluence (0 [None]- 4 [91-100%full epithelial growth]) - erythema (0 [None]- 4 [Severe]) - edema (0 [None]- 4 [Severe]) - crusting/scabbing (0 [None]- 4 [90-100% crusting/scabbing]). CHS on 25-point scale (-12 [no healing] to +12 [towards healing]) is indicative of extent of wound healing and was calculated for each wound site at each evaluation day. Up to Day 16
Secondary Change From Baseline in Trans-Epidermal Water Loss (TEWL) Measurements Change from Baseline in TEWL was reported. TEWL is the passive transfer of water through stratum corneum and was measured for each wound site using Tewameter TM330T. TEWL is a non-invasive method to measure the integrity of stratum corneum barrier function. Tewameter probe measures the density gradient of the water evaporation from the skin indirectly by two pairs of sensors (temperature and relative humidity) inside a hollow cylinder. The probe was held in place on the skin for one measurement, for 40 sec, to ensure that a stable value has been established. The values of the last 10 sec are averaged as the actual measurement values. An increase in TEWL values shows damage to the skin barrier function. Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14
Secondary Change From Baseline in Clinical Grading of Wound Healing Parameter - Erythema Change from baseline in Clinical grading of wound healing parameter (erythema) was evaluated on a scale of 0 (no erythema) to 4 (severe erythema). Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Secondary Change From Baseline in Clinical Grading of Wound Healing Parameter - Edema Change from baseline in Clinical grading of wound healing parameter (edema) was evaluated on a scale of 0 (no edema) to 4 (severe edema). Day 0 (immediate after wound creation), Day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16
Secondary Change From Baseline in Composite Scar Score Change from baseline in composite scar score was reported. It was calculated as the sum of the individual parameters on the Manchester Scar Scale (Color ranges 1 [perfect] to 4 [gross mismatch]), Finish ranges 1 [matte] to 2 [shiny], Contour ranges 1 [Flush with surrounding skin] to 4 [keloid], Distortion ranges 1 [none] to 4 [severe] and Texture ranges 1 [normal] to 4 [hard]). Composite Scar Scores range from 5 to 18, with 5 representing clinically best scars and 18 representing clinically worst scars. Baseline and Day 28
Secondary Change From Baseline in Painful Score With Arm Resting by Side Change from baseline in painful score based on participants self-assessment questionnaire score (question 1) was reported. Participants were asked to rate each wound for pain/soreness in resting position as score from 0 (no pain) to 10 (severe pain). Baseline, Day 1, 2, 3 and 4
Secondary Change From Baseline in Painful Score With Arm in Normal Motion Change from baseline in Painful Score based on participants self-assessment questionnaire score (question 3) was reported. Participants were asked to rate each wound for pain/soreness in normal position as score from 0 (no pain) to 10 (severe pain). Baseline, Day 1, 2, 3 and 4
Secondary Change From Baseline in Itchy Score Change from baseline in itchy score based on participants self-assessment questionnaire score (question 5) was reported. Participants were asked to rate each wound for itchiness as score from 0 (no itch) to 10 (severe itch). Baseline, Day 1, 2, 3 and 4
Secondary Number of Participants With Pain Duration With Arm Resting by Side Participants were asked to rate the pain as either brief, periodic, or constant in arm resting position with the Self-Assessment Questionnaire (question 2). Number of participants with pain duration (brief, periodic, or constant) with arm resting by side was reported. Day 1, 2, 3 and 4
Secondary Number of Participants With Pain Duration With Arm in Normal Motion Participants were asked to rate the pain as either brief, periodic, or constant in arm normal motion with the Self-Assessment Questionnaire (question 4). Number of participants with pain duration (brief, periodic, or constant) with arm in normal motion was reported. Day 1, 2, 3 and 4
See also
  Status Clinical Trial Phase
Completed NCT05045183 - A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated N/A
Enrolling by invitation NCT04613336 - Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
Recruiting NCT02241811 - Wound Treatment With 3% Sodium Pentaborate Pentahydrate Phase 1
Completed NCT02797899 - Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft N/A
Completed NCT01227759 - Tyrosur® Gel-Investigation on Wound Healing Efficacy Phase 2
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Completed NCT00736593 - A Study Evaluating Nexagon™ in the Treatment of Skin Wounds. Phase 1
Completed NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects Phase 1/Phase 2
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05191082 - Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate N/A
Enrolling by invitation NCT05942235 - The Use of Microlearning in Nursing Education
Completed NCT03433820 - Wound Healing in Healthy Volunteers N/A
Withdrawn NCT02383992 - Postoperative Care of Sutured Wounds N/A
Recruiting NCT02034539 - VADOplex Critical Limb Ischemia Study Phase 2/Phase 3
Recruiting NCT01680042 - Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy Phase 1
Completed NCT01734317 - An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver. N/A
Completed NCT01115218 - The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
Withdrawn NCT01008111 - Wound Healing of Incisional Wounds for Bilateral Hernia Repair Phase 1
Completed NCT00984503 - Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites Phase 2